Better Health for All

Moderna's core business, focused on mRNA vaccines and therapeutics for serious diseases, has positively impacted over 100 million lives globally, notably by protecting hundreds of millions from COVID-19

and lessening the pandemic's burden. The company has no identified harmful products. For price accessibility, Moderna provides its COVID-19 vaccines at no cost to all individuals in the United States, regardless of insurance status. The company demonstrates strong risk transparency by sharing clinical trial data, having a Transparency & Disclosure Policy, and requiring informed consent for trial participants. Moderna supports healthcare workforce development through a partnership aiming to train 80,000 professionals in Africa over ten years. Its healthcare data practices include safeguarding participant privacy and complying with HIPAA. Moderna has shown a strong global health crisis response, creating its Foundation in response to COVID-19, and donating $1.4 million to humanitarian crises in 2023. The company supports mental health through a partnership for a Good Grief Program for children affected by COVID-19 loss. Moderna exhibits patent flexibility with a commitment to Patent Non-Enforcement in low-income countries and offering its mRNA technology to researchers. Clinical trials adhere to high ethical standards, including independent IRB/EC review, informed consent, and robust monitoring, with an average enrollment of 38% Global Ethnic Majority participants in U.S. infectious disease trials. The company also engages in healthcare education, including STEM education and clinical training for the health workforce. However, the U.S. government canceled a $766 million contract for a bird flu vaccine due to the project not meeting necessary scientific or safety standards.

Fair Pay & Worker Respect

In 2024, an outside statistical pay equity analysis confirmed zero statistically significant differences in pay across gender globally and across gender, race, and ethnicity in the United States, marking the third consecutive year for this finding.

The company's voluntary turnover rate was approximately 6% in 2024. The CEO-to-median employee pay ratio stood at 93:1 in 2024, with the CEO receiving $19.87 million and the median employee earning $213,200. Moderna received a $6,000 penalty from the Occupational Safety and Health Administration (OSHA) in 2022 for a workplace safety or health violation.

Fair Trade & Ethical Sourcing

Moderna Inc. outlines its commitment to ethical sourcing and fair trade practices through corporate policies, including a Human Rights Policy and Modern Slavery Statement, emphasizing the prevention of exploitation, child labor, forced labor, and discrimination, and ensuring supply chain transparency.

The company's 2023 ESG Report highlights efforts in environmental, social, and governance. Moderna has committed to global vaccine access by agreeing to provide up to 650 million COVID-19 vaccine doses via COVAX and is investing in manufacturing expansion, including a future plant in Kenya. Shareholders have proposed an analysis of intellectual property and technology transfer for vaccine production in low-to-middle-income countries to enhance equitable access. As a biotechnology company focused on mRNA therapeutics and vaccines, Moderna's operations do not involve the sourcing of high-risk physical commodities such as conflict minerals or uncertified palm oil.

Honest & Fair Business

Moderna has an Anti-Bribery and Anti-Corruption Policy that references the Foreign Corrupt Practices Act

, states zero tolerance for corruption , and guides compliance with global laws and regulations , prohibiting bribes, kickbacks, improper payments, and certain entertainment . However, the policy's training frequency and effectiveness metrics are not specified. The company's whistleblower policy prohibits retaliation and offers multiple reporting channels , including a third-party managed anonymous hotline , but prefers employees to identify themselves and lacks explicit evidence of independent investigation processes. For third-party verification, all Moderna-sponsored clinical trials are reviewed and approved by independent Institutional Review Boards or Ethics Committees , and Data Safety Monitoring Boards provide independent review for certain trials . ERM CVS Assurance Statements are also available for various company reports .

Kind to Animals

Moderna conducted animal trials on mice and macaques for its COVID-19 mRNA vaccines

, as referenced in FDA Emergency Use Authorization forms , indicating that legal mandates for testing override alternatives. However, the company is also using a liver chip model to determine the safety of lipid nanoparticle delivery systems for RNA therapeutics, directly replacing non-human primate studies . These organ chip studies are significantly more efficient, costing less than one-tenth and taking one-fourth the time of non-human primate studies . Moderna has partnered with Emulate, an organ-chip maker, for this safety screening .

No War, No Weapons

Moderna has a Sustainable Procurement Program designed to assess and manage human rights risks in its value chain.

Of the suppliers assessed, 85% scored 'Good' or above against ethical expectations outlined in the Third Party Code of Business Conduct. The company's commitment embraces internationally recognized human rights, including the International Bill of Human Rights and ILO Core Labour Rights Conventions. Moderna integrates UN Guiding Principles into training, with 97% of employees completing Code of Ethics and Business Conduct training by the end of 2024.

Planet-Friendly Business

Moderna's net-zero emissions target for 2030 has been validated by the Science Based Targets initiative (SBTi).

This target includes a 90% reduction in Scope 1 and 2 GHG emissions by 2030, and a 90% reduction in Scope 3 emissions by 2045, with long-term goals to maintain these reductions through 2045. The company's operations run on 100% green energy, with 30% generated via solar panels. This renewable energy use reduces CO₂ emissions by 550 tons annually. Energy efficiency projects, such as HVAC upgrades, have further reduced greenhouse gas emissions by nearly 3,000 tons.

Respect for Cultures & Communities

Moderna has 8 formal partnerships with organizations such as the Mabel Center for Immigrant Justice, Boston Medical Center, Heading Home, International Rescue Committee, Life Science Cares, Year Up, Amref Health Africa, and Seed Global Health.

No cultural appropriation incidents are reported for Moderna. FPIC processes are noted as not applicable to Moderna's business model. Moderna's UNIDOS Employee Resource Group is named in Spanish and hosts Spanish lessons, demonstrating some language inclusivity efforts.

Safe & Smart Tech

Moderna has reported no material cybersecurity incidents as of February 2025, indicating no data breaches in the past three years

and no unauthorized data use incidents in recent years . The company states that critical and high severity vulnerabilities are addressed immediately . Moderna has a Coordinated Vulnerability Disclosure program but does not offer a bug bounty . The company has an AI Code of Conduct , and 86% of its senior leaders have participated in AI training . Moderna aims to comply with major global privacy regulations including GDPR, CCPA, and APPI . Its privacy statement outlines a commitment to privacy by design principles, such as limiting personal data collection to what is necessary and storing it only as long as needed . Users are provided with standard controls over their personal data, including rights to access, correct, delete, and data portability .

Zero Waste & Sustainable Products

No specific, quantifiable evidence was found in the provided article for any of the KPIs related to Zero Waste & Sustainable Products. The article mentions general environmental sustainability initiatives, such as waste assessments at one manufacturing facility to identify opportunities, and targets for LEED certifications for new facilities, but does not provide metrics on waste diversion rates, product recyclability, packaging sustainability, recycled content, waste reduction percentages, take-back programs, or certifications achieved. It also refers to carbon emission targets, which are not directly related to waste management KPIs. The company has committed to achieving net-zero carbon emissions for Scope 1 and 2 by 2030 and for Scope 3 by 2045.

In 2023, Moderna reported Scope 1 emissions of approximately 11,240 metric tons of CO₂ equivalent and Scope 2 emissions of about 11,506 metric tons of CO₂ equivalent. To support these goals, Moderna has incorporated sustainable design elements into new facilities, such as the Moderna Science Center in Cambridge, Massachusetts, which targets LEED Platinum Core & Shell and LEED Zero Carbon certifications. Additionally, the company has implemented energy, water, and waste assessments at its Norwood, Massachusetts manufacturing facility to identify opportunities for reducing fossil fuel and water usage, improving operational efficiency, and enhancing waste management programs. Moderna also encourages green transportation among employees by offering fully subsidized public transport, bike sharing, and free electric vehicle charging stations across its campuses.